KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash & Current Investments (2016 - 2025)

Abbott Laboratories' Cash & Current Investments history spans 17 years, with the latest figure at $8.9 billion for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 12.2% year-over-year to $8.9 billion; the TTM value through Dec 2025 reached $8.9 billion, up 12.2%, while the annual FY2025 figure was $8.9 billion, 12.2% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $8.9 billion at Abbott Laboratories, up from $7.7 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $10.2 billion in Q4 2021 and bottomed at $6.7 billion in Q1 2024.
  • The 5-year median for Cash & Current Investments is $8.2 billion (2022), against an average of $8.4 billion.
  • The largest annual shift saw Cash & Current Investments soared 128.24% in 2021 before it tumbled 30.22% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $10.2 billion in 2021, then fell by 0.77% to $10.2 billion in 2022, then fell by 28.43% to $7.3 billion in 2023, then increased by 9.45% to $8.0 billion in 2024, then rose by 12.2% to $8.9 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Cash & Current Investments are $8.9 billion (Q4 2025), $7.7 billion (Q3 2025), and $7.3 billion (Q2 2025).